Keywords
IgG
Escala de Bhalla
Errores innatos de la inmunidad
Calidad de vida
Abstract
Objective: To establish the prevalence of bronchiectasis, correlate the IgG IV or SC immunoglobulin dose and serum IgG levels with the total Bhalla score and the severity of bronchiectasis and associate serum IgG levels with the development of pulmonary infectious processes in patients with diagnosis of innate errors of immunity.
Methods: A descriptive, observational, cross-sectional study with patients over 18 years of age diagnosed with IBD. Clinical records and computed axial tomography were reviewed.
Results: 38 patients with IBD were included, where the prevalence of bronchiectasis was 36.8%. (Regarding the correlation of pulmonary infectious processes with serum IgG levels, a difference was found in patients from 2020 to 2022 (p= 0.002, 0.054, 0.030 respectively). The correlation of severity of bronchiectasis, total score of Bhalla scale, IgG IV or SC immunoglobulin dose and serum IgG levels by Spearman’s Rho test I were found to be significantly correlated.
Conclusion: It is important to perform chest tomography studies every 3-4 years in patients with IBD to detect timely bronchiectasis, initiate treatment in time, improving patients’ quality of life and survival rates, and reducing hospital costs.
Keywords: Bronchiectasis; IgG, Bhalla score; Inborn errors of immunity; Quality of life.
References
Bonilla F, Khan D, Ballas Z, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Inmmunol 2015; 136 (5): 1186-205.e1-78. https://doi.org/10.1016/j.jaci.2015.04.049
Hill A, Sullivan A, Chalmers J, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2018; 74: 1-69. https://doi.org/10.1136/thoraxjnl-2018-212463
Imam JS, Duarte A. Non-CF bronchiectasis: Orphan disease no longer. Resp Med 2020; 166: 105940. https://doi.org/10.1016/j.rmed.2020.105940
Velásquez-Ortiz María Guadalupe, O’Farrill-Romanillos Patricia María, Berrón-Ruiz Laura. Conceptos generales de las inmunodeficiencias humorales. Rev Alergia Méx 2020; 67 ( 2 ): 142-164. https://doi.org/10.29262/ram.v67i2.763
Chalmers J, Hill A. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Moll Inmmunol 2013; 55 (1): 27-34. https://doi.org/10.1016/j.molimm.2012.09.011
Lonni S, Chalmers J, Goeminne P, et al. Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Ann Am Thorac Soc 2015; 12 (12): 1764-70. https://doi.org/10.1513/AnnalsATS.201507-472OC
Chalmers JD, Goeminne P, Aliberti S, et al. Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med 2014; 189: 576-585.
Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991; 179 (3): 783-8. https://doi.org/10.1148/RADIOLOGY.179.3.2027992
Vivas-Rosales IJ, Hernández-Ojeda M, O’Farrill-Romanillos PM, Herrera-Sánchez DA, et al. Severidad de bronquiectasias en pacientes adultos con inmunodeficiencia común variable. Rev Alergia Méx 2018; 65 (3): 242-249. https://doi.org/10.29262/ram.v65i3.399.
Hernández-Ojeda M, Vivas-Rosales IJ, Mendoza-Reyna LD, Múzquiz-Zermeño D, et al. Tipo y localización de bronquiectasias en una cohorte de adultos con inmunodeficiencia común variable. Rev Méd IMSS 2017; 55 (4): 414-418.
King P. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009; 4: 411-419. https://doi.org/10.2147/COPD.S6133
Mogica MM, García LS, Silva VR, Montaño VB, Cruz MA. Neumopatías en pacientes con inmunodeficiencias primarias en tratamiento con gammaglobulina intravenosa. Rev Alerg Mex 2007; 54 (1): 14-19.
Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116 (1): 7-15. https://doi.org/10.1182/blood-2010-01-254417
Wall L, Wisner EL, Gipson K, Sorensen R. Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach. Front Immunol 2020; 11: 522. https://doi.org/10.3389/fimmu.2020.00522
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2024 Revista Alergia México